Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy

The clinical success of immune-checkpoint inhibitors (ICI) in both resected and metastatic melanoma has confirmed the validity of therapeutic strategies that boost the immune system to counteract cancer. However, half of patients with metastatic disease treated with even the most aggressive regimen...

Descripción completa

Detalles Bibliográficos
Autores principales: Pickering, Chad, Aiyetan, Paul, Xu, Gege, Mitchell, Alan, Rice, Rachel, Najjar, Yana G., Markowitz, Joseph, Ebert, Lisa M., Brown, Michael P., Tapia-Rico, Gonzalo, Frederick, Dennie, Cong, Xin, Serie, Daniel, Lindpaintner, Klaus, Schwarz, Flavio, Boland, Genevieve M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302726/
https://www.ncbi.nlm.nih.gov/pubmed/37388743
http://dx.doi.org/10.3389/fimmu.2023.1187332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302726/
https://www.ncbi.nlm.nih.gov/pubmed/37388743
http://dx.doi.org/10.3389/fimmu.2023.1187332

Ejemplares similares